Related by context. All words. (Click for frequent words.) 84 CI = 82 % CI #.#-#.# [002] 81 % CI #.#-#.# [006] 80 confidence interval #.#-#.# 77 % CI #.#-#.# [007] 76 CI #.#-#.# [002] 76 % CI #.#-#.# [003] 76 CI -#.# 76 P = .# 75 p = .# [002] 75 % CI #.#-#.# [008] 75 p = 72 % Confidence Interval 71 p = #.# [002] 71 % CI #.#-#.# [001] 70 confidence intervals CIs 70 p = #.# [004] 70 placebo p = 69 multivariable adjusted 69 nonfatal MI 68 AOR = 68 % CI #.#-#.# [004] 68 interquartile range 68 p = NS 67 CI #.#-#.# [001] 67 aOR 67 recurrent VTE 67 univariate analysis 67 recurrent venous thromboembolism 67 neurodevelopmental impairment 67 creatinine ratio 66 p = #.# [003] 66 mL/min/#.# m 2 66 n = 66 advanced adenoma 66 NNT = 66 mIU L 66 P ≤ 66 pg mL 66 MADRS score 65 nonsignificant 65 μmol L 65 HbA 1c levels 65 pmol L 65 -#.# ± [002] 65 CI #.#-#.# p = 65 tertile 65 nonsignificant difference 65 sd = 65 adjunctive placebo 65 postintervention 65 reinfarction 65 highest tertile 65 tirofiban 65 statistically significant p = 65 mcg QD 65 x ULN 64 #.#/#.# mmHg [001] 64 FOLFIRI alone 64 hip BMD 64 lowest tertile 64 p ≤ 64 leukopenia 64 MetS 64 ipsilateral stroke 64 alanine aminotransferase 64 biochemical recurrence 64 nonobese 64 pg ml 64 mmol l 64 mild renal impairment 64 hours postdose 64 ALT elevation 64 nmol L 64 = #.#-#.# 64 chlorambucil 63 odds ratios ORs 63 colorectal adenoma 63 mmol L 63 nonfatal myocardial infarction 63 logistic regression analysis 63 nondiabetic patients 63 TT genotype 63 mmHg diastolic 63 #mg/day [001] 63 parous women 63 baseline HbA1c 63 arterial thromboembolic events 63 CC genotype 63 ng mL 63 p = .# [001] 63 biochemical relapse 63 lispro 63 serum concentrations 63 MACCE 63 lopinavir r arm 63 severe neutropenia 63 oxycodone CR 63 severe exacerbations 63 hypophosphatemia 63 amoxicillin clavulanate 63 seropositivity 63 definite stent thrombosis 63 nmol liter 63 β = 63 achieved ACR# 63 HBeAg negative patients 63 g dL 63 Secondary endpoints included 63 COPD exacerbation 63 progression TTP 62 posttreatment 62 Secondary endpoints include 62 HBeAg negative 62 mg d 62 tolterodine ER 62 nadroparin 62 febrile neutropenia 62 nmol 62 Kaplan Meier analysis 62 nonfatal stroke 62 leucopenia 62 CrCl 62 postoperative AF 62 placebo p 62 preintervention 62 pT3 62 SGPT 62 r = 62 Baseline characteristics 62 μg kg 62 intima media thickness 62 mU liter 62 multivariate Cox 62 -#.# mg dL [002] 62 advanced adenomas 62 % CI #.#-#.# [005] 62 pCR 62 â ‰ ¥ 62 CR nPR 62 deep venous thromboses 62 tipranavir r 62 5-FU/LV 62 g dl 62 posttransplant 62 QTcF 62 MMSE score 62 nmol l 62 clodronate 62 univariate analyzes 62 euthyroid 62 comparator arm 62 chlorthalidone 62 WOMAC pain 62 endometrial thickness 62 intact parathyroid hormone 62 locoregional recurrence 61 thromboembolism 61 liver histology 61 TEAEs 61 pmol liter 61 HbA 1c 61 Hazard Ratio HR 61 elevated ALT 61 periprocedural 61 dyspnea 61 TAXUS p value 61 multivariate adjusted 61 abacavir lamivudine 61 morphometric vertebral fractures 61 MMSE scores 61 annualized relapse 61 HbA1C levels 61 statistically significant p 61 CYP#D# inhibitor 61 invasive carcinomas 61 ≥ 61 Hazard Ratio 61 polyp recurrence 61 perioperatively 61 postoperative complication 61 Hb A1C 61 mEq L 61 mmHg p = 61 mcg mL 61 nicardipine 61 lymphocytosis 61 mcg BID 61 FluCAM arm 61 generalized edema 61 adjunctive ABILIFY 61 postop 61 HF hospitalization 61 lumbar spine BMD 61 microg 61 receiving ISENTRESS 61 binary restenosis 61 overt nephropathy 61 lymph node metastasis 61 multivariate adjustment 61 rs# [004] 61 ng ml 61 adefovir treated 61 tertiles 61 creatinine clearance 61 neutrophil counts 61 atazanavir ritonavir 61 noncardiac 61 β blockers 61 nonvertebral fractures 61 extracapsular extension 61 CR CRu 60 IQR 60 certolizumab 60 mIU ml 60 rebleeding 60 CVD mortality 60 detrusor overactivity 60 alanine aminotransferase ALT 60 hsCRP levels 60 mg kg dose 60 symptomatic VTE 60 composite endpoint 60 IIIa inhibitors 60 systolic BP 60 GnRH agonist 60 genotypic resistance 60 DAS# [002] 60 μg dL 60 mU L 60 β blocker 60 recurrent atrial fibrillation 60 4mg/kg 60 log# copies mL 60 multivariate analysis 60 fasting triglyceride levels 60 glycated hemoglobin levels 60 leukocyte count 60 df = 60 CCyR 60 ug kg 60 urine albumin 60 psychiatric comorbidities 60 univariate 60 cerebrovascular events 60 achieved statistical significance 60 NMIBC 60 cilostazol 60 ATACAND 60 estimated glomerular filtration 60 hepatorenal syndrome 60 advanced neoplasia 60 renal insufficiency 60 nonexposed 60 highest quintile 60 umol L 60 receiving VICTRELIS 60 plus medroxyprogesterone acetate 60 diastolic BP 60 median PFS 60 perioperative complications 60 -#.# mg dL [001] 60 PRADAXA #mg 60 LV dysfunction 60 p = ns 60 Flu Cy 60 baseline LDH 60 hematologic toxicity 60 AUCs 60 recurrent DVT 60 hypoxemia 60 pentoxifylline 60 statistical significance p 60 REYATAZ r arm 60 dalteparin 60 antibody titer 60 octreotide LAR 60 HBeAg positive patients 60 lopinavir r 60 PCWP 60 mild renal insufficiency 60 Hb A1c 60 progesterone receptor negative 60 covariates 60 fatigue asthenia 60 pericardial effusion 60 multivariate analyzes 60 ischemia driven 60 preoperative PSA 60 #mg BID [003] 60 nasopharyngitis 60 thromboembolic events 60 thromboprophylaxis 60 pretest probability 60 multivariable analysis 60 autonomic dysfunction 60 -#.# log# copies mL 60 laboratory abnormalities 60 PSA nadir 60 #mg BID [001] 60 imipenem 59 EDSS score 59 PaO 2 59 rs# [003] 59 μg mL 59 #mmHg [002] 59 proximal DVT 59 NATRECOR R 59 distant metastasis 59 mg p = 59 extrapyramidal symptoms 59 KRAS mutations occur 59 ß = 59 Ishak fibrosis score 59 diastolic hypertension 59 methotrexate monotherapy 59 refractory ischemia 59 aspartate aminotransferase 59 flutamide 59 histologic subtype 59 mL kg 59 thromboembolic 59 attain statistical significance 59 logistic regression model 59 #q# deletion syndrome 59 tapentadol ER 59 Stent thrombosis 59 μg d 59 methacholine challenge 59 nondiabetic 59 serum ALT 59 #.#-#.# p = 59 thrombocytopenic 59 HbA1c levels 59 Score TOS 59 eplerenone 59 discontinuations due 59 carotid IMT 59 timepoints 59 Complication rates 59 corrected QT interval 59 Subgroup analyzes 59 quetiapine risperidone 59 tHcy 59 RLAI 59 Index CDAI 59 atopic asthma 59 abdominal pain abdominal discomfort 59 ± 59 #mg QD [001] 59 -#.# ± [001] 59 asthma exacerbation 59 dysuria 59 seronegative 59 trimethoprim sulfamethoxazole 59 AUC0 59 ß blockers 59 mol L 59 LV ejection fraction 59 adenoma recurrence 59 Hazard Ratio = 59 preoperative 59 μg L 59 PCa 59 ug dose 59 fasting insulin 59 erythrocyte sedimentation rate 59 kappa = 59 recurrent UTI 59 histologically confirmed 59 mm Hg diastolic 59 renal scarring 59 virologic failure 59 Zometa hazard 59 tipranavir ritonavir 59 HRQoL 59 uM 59 LVEF 59 FOLFOX4 59 log# reduction 59 Acetate Rectal Suppositories 59 BMI ≥ 59 vertebral fracture 59 Secondary endpoints 59 fluticasone salmeterol 59 plasma uric acid 59 hemorrhagic complications 59 preoperatively 59 CIMZIA TM certolizumab pegol 59 System IPSS 59 ximelagatran 59 mitoxantrone 59 systemic embolism 59 asthenia 59 cGy 59 Operative mortality 59 nonvertebral fracture 59 myocardial infarction stroke 59 postdischarge 58 affective psychosis 58 virological failure 58 LVSD 58 titrated glipizide 58 mmHg systolic 58 URTI 58 normotensive 58 % AST SGOT 58 neutropenic sepsis 58 plus GP IIb 58 mg ustekinumab 58 coinfected patients 58 de novo AML 58 infliximab monotherapy 58 Erythropoietic therapies may 58 adenomatous 58 rs# [002] 58 placebo 58 moderately emetogenic 58 PREZISTA r 58 #.#/#.# mm Hg [003] 58 HBeAg seroconversion 58 thyrotropin levels 58 clomipramine 58 incidence ≥ 58 Apgar scores 58 ARCOXIA 58 Postoperatively 58 tamsulosin 58 serum potassium 58 oral allopurinol 58 milliliters mL 58 noncarriers 58 rheumatoid factor 58 TMP SMX 58 androgen suppression 58 PROCTOCORT ® Suppository Hydrocortisone 58 AST ALT 58 nodal metastases 58 CIN3 58 ng dL 58 NPH insulin 58 #OHD 58 thromboembolic complications 58 PANSS scores 58 Folfox 58 bronchopulmonary dysplasia 58 serum urate levels 58 comorbidity 58 ug ml 58 stent binary restenosis 58 placebo fluoxetine 58 elevated IOP 58 proteinuria 58 microbiological eradication 58 underwent resection 58 ALT flares 58 serum IGF 58 Multivariate analysis 58 aspartate aminotransferase AST 58 ml kg 58 nonalcoholic steatohepatitis NASH 58 doxazosin 58 unfractionated heparin 58 aged ≥ 58 -#.# log# 58 nonischemic 58 echocardiographic parameters 58 hormone receptor negative 58 hypercalciuria 58 hemoglobin A1c HbA1c 58 mg QD 58 Brief Psychiatric 58 cardiovascular hospitalizations 58 Primary endpoints 58 serum estradiol 58 isoproterenol 58 achieved CCyR 58 sodium nitroprusside 58 tumor histology 58 plus aztreonam 58 ± SD 58 elevated transaminases 58 arthralgia 58 ziprasidone 58 complete cytogenetic response 58 ventricular tachyarrhythmia 58 SUVmax 58 acute cholecystitis 58 microbiologically evaluable 58 symptomatic intracerebral hemorrhage 58 mg TID 58 vesicoureteral reflux 58 XIENCE V PROMUS Stent 58 coronary revascularization 58 hypokalemia 58 desvenlafaxine succinate 58 plasma creatinine 58 latent celiac disease 58 venous thromboembolic disease 58 hypomagnesemia 58 mechanically ventilated patients 58 endometrial carcinoma 58 pooled comparator 58 multivariable Cox 58 SGRQ 58 platelet reactivity 58 oxycodone IR 58 sociodemographic characteristics 58 atrophic gastritis 58 ertapenem 58 noninferiority 58 log# IU mL 58 CsA 58 Visual Analogue Scale VAS 58 lactate dehydrogenase 58 IPSS 58 BPS IC 58 nasopharyngitis headache 58 aldosterone antagonist 58 adenotonsillectomy 58 BARACLUDE ® 58 HIV uninfected 58 nmol L. 58 #.#ng/ml 58 #mg doses [002] 58 ‰ ¥ 58 underwent surgical resection 58 PREMPRO 58 dapagliflozin plus 58 idraparinux 58 mcg kg 58 femoral neck BMD 58 HOMA IR 58 femoral neck fracture 58 invasive ductal 58 interleukin IL -6 58 systolic dysfunction 58 IOP lowering 58 troponin T 58 nonobstructive 58 mg + GLY 58 Logistic regression 58 hepatic metastases 58 left ventricular systolic 58 neutropenic fever 58 thyroid carcinoma 58 intravesical therapy 58 ECOG PS 58 moderate renal impairment 58 mcg kg REBETOL 58 mL/min/#.# m2 57 nonfasting triglyceride levels 57 8mg/kg 57 extensive metabolizers 57 microalbuminuria 57 rs# [001] 57 apnea hypopnea index 57 Cmax 57 corticosteroid dose 57 ischemic lesions 57 linaclotide treated 57 relapsed MM 57 antiandrogen 57 events MACE 57 stomatitis 57 prednisone prednisolone plus 57 tumor recurrence 57 stage IIIb IV 57 LAB GHRH 57 BMI z 57 QRS duration 57 CIN2 + 57 experienced virologic failure 57 FLT3 ITD 57 glomerular filtration 57 #.#mmHg 57 elevated serum creatinine 57 paresthesias 57 Partial Response 57 mesalamine granules 57 APTIVUS r 57 heterozygotes 57 severe renal impairment 57 sUA 57 daunorubicin 57 rizatriptan 57 external genital lesions 57 placebo dexamethasone 57 mcg albinterferon alfa 2b 57 endometrial hyperplasia 57 transaminase elevations 57 PREZISTA r arm 57 gastrointestinal perforation 57 hemodynamically significant 57 RBC transfusion 57 Y BOCS 57 cerebrovascular accidents 57 #mg/day [002] 57 venlafaxine XR 57 hypertensives 57 HER2 expression 57 μg ml 57 aspirin clopidogrel 57 solifenacin 57 mucosal inflammation 57 elevated lipase 57 contrast induced nephropathy 57 HBeAg 57 ATV RTV 57 subclinical hyperthyroidism 57 Platelet counts 57 bronchial hyperresponsiveness 57 sensory neuropathy 57 primary aldosteronism 57 squamous histology 57 prospectively defined 57 polytherapy 57 budesonide pMDI 57 obstructive coronary artery 57 CDAI 57 intratympanic 57 CHD mortality 57 homozygotes 57 comorbid 57 #mg QD [002] 57 preterm neonates 57 mg kg Hematide 57 adriamycin 57 salmeterol fluticasone propionate 57 #.#mg/dL 57 ropivacaine 57 interquartile range IQR 57 EBRT 57 diuretic chlorthalidone 57 NSTEMI 57 hematuria 57 serum TSH 57 urinary excretion 57 histological subtype 57 mg BID dose 57 min -1 57 UGT#A# * 57 elevated LDH 57 K ras mutations 57 heparin induced thrombocytopenia 57 glycoprotein IIb IIIa inhibitors 57 QVAR R 57 mcg dL 57 atopic 57 aminotransferase elevations greater 57 mm Hg systolic 57 neurologic complications 57 hydronephrosis 57 serum PTH 57 diameter stenosis 57 HbA1C 57 Univariate analysis 57 HAQ DI 57 nonpregnant women 57 atopy 57 poor metabolizers 57 biopsy Gleason 57 rho = 57 NNRTI resistance 57 comorbid anxiety 57 plasma folate 57 FDA defined valvulopathy 57 colorectal neoplasia 57 macroalbuminuria 57 airway responsiveness 57 XIENCE V vs. 57 irbesartan 57 Pneumocystis carinii pneumonia 57 postoperatively 57 plasma cortisol 57 breast carcinoma 57 gestational hypertension 57 nulliparous women 57 SSRI SNRI 57 hyperphenylalaninemia HPA due 57 salmeterol HFA MDI 57 adenomatous polyps 57 prostate cancer CaP 57 Thal Dex 57 LPV r 57 glycated hemoglobin HbA1c 57 atherothrombotic 57 upper gastrointestinal bleeding 57 r2 = 57 comorbidities 57 #ng/ml 57 spinal cord compression 57 colorectal adenomas 57 comorbid depression 57 albumin excretion 57 cerebral oxygenation 57 F FDG PET 57 serum creatinine levels 57 IFN alfa 57 transferrin saturation 57 HGPIN 57 prospectively stratified 57 partial remissions 57 mycophenolate 57 NIHSS score 57 non valvular atrial 57 racemic albuterol 57 pyrexia 57 hepatic enzymes 57 NIH CPSI 57 ENDOMETRIN 57 reintubation 57 severe hypoglycemic 57 Pred Forte 57 response pCR 57 PLX STROKE targeting 57 recurrent ischemia 57 mg BID 57 response CCyR 57 glomerular filtration rate 57 myocardial infarction MI 57 MBq 57 coronary stenosis 57 Fasting plasma glucose 57 Score DAS# 57 carotid stenosis 57 nonmetastatic 57 colorectal neoplasms 57 Partial Responses 57 IU ml 57 VT VF 57 nonobese patients 57 Crohn Disease Activity 57 esophageal carcinoma 57 prevalences 57 adnexal mass 57 mg tid 57 oral antidiabetic medication 57 non splenectomized 57 free survival PFS 57 TURBT 57 Median PFS 57 -#.# mm Hg 57 metastatic malignant 56 reach statistical significance 56 pulmonary dysfunction 56 IM progesterone 56 preoperative chemotherapy 56 arterial oxygen saturation 56 lacunar 56 lymphopenia 56 EDSS scores 56 pegylated interferon alfa 2b 56 Cream USP 1 56 FOLFOX 56 DAS# remission 56 locoregional disease 56 rFSH 56 overt hepatic encephalopathy HE 56 BENICAR HCT 56 cranial irradiation 56 labetalol 56 postoperative mortality 56 serum cortisol 56 carotid intima media 56 Breslow thickness 56 CANCIDAS 56 urinary bladder cancer 56 serum phosphorous 56 conjunctival hyperemia 56 airflow obstruction 56 androgen deprivation 56 pretransplant 56 seroprotection 56 euthymic patients 56 oral prednisolone 56 voriconazole 56 prolonged QT interval 56 symptomatic intracranial 56 HIV RNA 56 virologic response 56 urate lowering therapy 56 pyelonephritis 56 Median progression 56 microgram kg 56 serum phosphorus 56 dyspareunia 56 adverse cytogenetics 56 subclinical hypothyroidism 56 micafungin 56 #mmHg [001] 56 neutropaenia 56 spontaneous bacterial peritonitis 56 pyrexia mucositis sepsis febrile 56 ml min 56 SRBD 56 nodal metastasis 56 symptomatic intracranial hemorrhage 56 hypoglycemic events 56 postoperative pulmonary 56 pT2 56 SCr 56 nucleoside naive 56 ejection fractions 56 glulisine 56 LEXIVA r 56 invasive aspergillosis 56 antiretroviral naïve 56 shorter telomere length 56 -#.# p = 56 tibiofemoral 56 HRCT 56 lowest quintile 56 5mg dose 56 postmenopausal osteoporotic women 56 subtrochanteric 56 concomitant medications 56 headache abdominal pain 56 otamixaban 56 angiotensin II receptor blockers 56 cerebral infarction 56 cm H2O 56 BUPHENYL R sodium phenylbutyrate 56 anastomotic leak 56 urinary albumin excretion 56 Serum creatinine 56 cytogenetic abnormalities 56 asymptomatic PAD 56 primidone 56 allergic eczema 56 renal dysfunction 56 QTc prolongation 56 NRTI sparing 56 ACR Pedi 56 diabetes mellitus DM 56 median survivals 56 mg kg 56 recurrent glioblastoma multiforme 56 IQR = 56 parasitaemia 56 depressive symptomatology 56 atheroma volume 56 pamidronate 56 headache nasopharyngitis 56 axillary node 56 alkaline phosphatase 56 postoperative complications 56 IIIa inhibitor 56 systolic blood pressures 56 neutropenia dehydration dyspnea 56 prespecified secondary 56 serum magnesium 56 Median survival 56 baseline FEV 56 IPAH 56 tumor lysis syndrome 56 cyclophosphamide methotrexate 56 sociodemographic factors 56 baseline serum creatinine 56 retrospective cohort 56 abciximab 56 mL sec 56 diastolic pressures 56 postoperative morbidity 56 clinicopathological features 56 urolithiasis 56 Kaplan Meier survival 56 papillary renal cell carcinoma 56 MELD scores 56 HER2 amplification 56 mean baseline A1C 56 affective psychoses 56 serum aminotransferase levels 56 chlamydial infection 56 colorectal carcinoma 56 nadolol 56 invasive lobular 56 peripheral edema 56 Montgomery Åsberg Depression 56 TDF FTC 56 gastroduodenal 56 evaluable 56 logistic regression analyzes 56 LNG IUS 56 ezetimibe simvastatin 56 recurrent acute pancreatitis 56 hypercholesterolaemia 56 μg 56 BRCA1 mutation carriers 56 nonresponders 56 sirolimus stent 56 symptomatic pulmonary embolism 56 Kaplan Meier estimates 56 seminal vesicle invasion 56 binary restenosis rate 56 T1c 56 Mg Uk 56 bronchioloalveolar carcinoma 56 ovarian carcinoma 56 apolipoprotein B 56 comorbid illnesses 56 plus glycoprotein IIb 56 peripheral sensory neuropathy 56 baseline Hb 56 GERD symptom 56 postprocedure 56 HDRS 56 hyperlipidaemia 56 clinically evaluable patients 56 mg dose 56 vasopressor 56 elevated hsCRP 56 CDAI score 56 DAS# scores 56 elevated creatinine 56 cerebrovascular accident 56 ritonavir boosted 56 ABCB1 56 hepatocellular carcinomas 56 anemia hemoglobin 56 arteriolar 56 haematologic 56 indinavir 56 undetectable HBV DNA 56 collagenous colitis 56 systemic corticosteroids 56 albumin excretion rate 56 timepoint 56 osteopenic 56 kg -1 56 antithymocyte globulin 56 nonfatal myocardial infarction MI 56 Response Evaluation Criteria 56 radical nephrectomy 56 inhospital mortality 56 conditional logistic regression 56 mcg linaclotide 56 ABC/3TC 56 mRNA expression 56 PSADT 56 steroid dexamethasone 56 IBDQ 56 DAS# CRP 56 revascularizations 56 proximal colon 56 conventional antipsychotics 56 akathisia 56 #.#mmol L [001] 56 pulmonary arterial 56 inhospital 56 lamivudine refractory patients 56 serum uric acid 56 cryptogenic 56 ipsilateral 56 cervicitis 56 efavirenz EFV 56 glimepiride 56 Rating Scale MADRS 56 kg/m2 56 subscales 56 venous thrombosis 56 GH deficiency 56 Helicobacter pylori eradication 56 highly emetogenic 56 HMG CoA reductase inhibitors 56 dietary calcium intake 56 carotid plaques 56 Exclusion criteria 56 locoregional 56 neoplasias 56 lamivudine monotherapy 56 SSRI citalopram 56 postoperative infections 56 intraobserver 56 normothermic 56 nM 56 death reinfarction 56 elevated troponin 56 μg liter 56 clopidogrel 56 recurrent wheezing 55 Suicidal ideation 55 T2DM 55 posaconazole 55 Myocardial infarction 55 PASI scores 55 antiemetics 55 Xalatan R 55 kcal d 55 μg doses 55 mg/# hours 55 rehospitalization 55 endoscopic remission 55 systemic corticosteroid 55 serum homocysteine 55 Lucentis monotherapy 55 mL min 55 Postoperative complications 55 achieved mucosal healing